UBS analyst Joseph Parkhill maintains Fluor (NYSE:FLR) with a Neutral and raises the price target from $26 to $36.
Shuttle Pharma Expands Patent Coverage On HDAC Inhibitor Platform
The Company's HDAC pre-clinical inhibitor platform includes:SP-2-225 is Shuttle Pharma's pre-clinical Class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6. SP-2-225 has effects on the regulation of
